Authors:
H Song, SJ Ramus, J Tyrer, KL Bolton, A Gentry-Maharaj, E Wozniak, H Anton-Culver, J Chang-Claude, DW Cramer, R DiCioccio, T Dörk, EL Goode, MT Goodman, JM Schildkraut, T Sellers, L Baglietto, MW Beckmann, J Beesley, J Blaakaer, ME Carney, S Chanock, Z Chen, JM Cunningham, E Dicks, JA Doherty, M Dürst, AB Ekici, D Fenstermacher, BL Fridley, G Giles, ME Gore, I De Vivo, P Hillemanns, C Hogdall, E Hogdall, ES Iversen, IJ Jacobs, A Jakubowska, D Li, J Lissowska, J Lubiński, G Lurie, V McGuire, J McLaughlin, K Medrek, PG Moorman, K Moysich, S Narod, C Phelan, C Pye, H Risch, IB Runnebaum, G Severi, M Southey, DO Stram, FC Thiel, KL Terry, Y-Y Tsai, SS Tworoger, DJ Van Den Berg, RA Vierkant, S Wang-Gohrke, PM Webb, LR Wilkens, AH Wu, H Yang, W Brewster, A Ziogas, Australian Cancer (Ovarian) Study, Australian Ovarian Cancer Study Group, Ovarian Cancer Association Consortium, R Houlston, I Tomlinson, AS Whittemore, MA Rossing, BAJ Ponder, CL Pearce, RB Ness, U Menon, SK Kjaer, J Gronwald, M Garcia-Closas, PA Fasching, DF Easton, G Chenevix-Trench, A Berchuck, PDP Pharoah, SA Gayther
Journal name: 
Nat Genet
Citation info: 
41(9):996-1000
Abstract: 
Epithelial ovarian cancer has a major heritable component, but the known susceptibility genes explain less than half the excess familial risk. We performed a genome-wide association study (GWAS) to identify common ovarian cancer susceptibility alleles. We evaluated 507,094 SNPs genotyped in 1,817 cases and 2,353 controls from the UK and approximately 2 million imputed SNPs. We genotyped the 22,790 top ranked SNPs in 4,274 cases and 4,809 controls of European ancestry from Europe, USA and Australia. We identified 12 SNPs at 9p22 associated with disease risk (P < 10(-8)). The most significant SNP (rs3814113; P = 2.5 x 10(-17)) was genotyped in a further 2,670 ovarian cancer cases and 4,668 controls, confirming its association (combined data odds ratio (OR) = 0.82, 95% confidence interval (CI) 0.79-0.86, P(trend) = 5.1 x 10(-19)). The association differs by histological subtype, being strongest for serous ovarian cancers (OR 0.77, 95% CI 0.73-0.81, P(trend) = 4.1 x 10(-21)).
DOI: 
http://doi.org/10.1038/ng.424
Research group: 
Ponder Group
E-pub date: 
01 Sep 2009